Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001204905 | SCV001376134 | uncertain significance | Neurofibromatosis, type 1 | 2020-07-24 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with NF1-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with aspartic acid at codon 1896 of the NF1 protein (p.Ala1896Asp). The alanine residue is moderately conserved and there is a moderate physicochemical difference between alanine and aspartic acid. |
| Ambry Genetics | RCV002348665 | SCV002653313 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2022-10-11 | criteria provided, single submitter | clinical testing | The p.A1896D variant (also known as c.5687C>A), located in coding exon 38 of the NF1 gene, results from a C to A substitution at nucleotide position 5687. The alanine at codon 1896 is replaced by aspartic acid, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |